Bolt Biotherapeutics (NASDAQ:BOLT) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Bolt Biotherapeutics (NASDAQ:BOLT) in a research report report published on Friday,Benzinga reports. They currently have a $7.00 price target on the stock.

BOLT has been the topic of a number of other reports. Zacks Research lowered shares of Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 20th. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, January 21st. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $34.00.

Bolt Biotherapeutics Stock Down 3.5%

Shares of BOLT opened at $3.91 on Friday. The stock has a market capitalization of $7.51 million, a PE ratio of -0.22 and a beta of 0.94. Bolt Biotherapeutics has a 1 year low of $3.91 and a 1 year high of $9.66. The company has a debt-to-equity ratio of 0.65, a quick ratio of 3.57 and a current ratio of 3.57. The company’s 50-day simple moving average is $5.40 and its 200-day simple moving average is $5.36.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($3.84) EPS for the quarter, beating the consensus estimate of ($4.27) by $0.43. The business had revenue of $2.50 million during the quarter, compared to analyst estimates of $0.67 million. Bolt Biotherapeutics had a negative net margin of 433.74% and a negative return on equity of 85.03%. Analysts forecast that Bolt Biotherapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Trading of Bolt Biotherapeutics

A number of large investors have recently made changes to their positions in the company. Squarepoint Ops LLC raised its holdings in Bolt Biotherapeutics by 19.8% in the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after acquiring an additional 2,448 shares in the last quarter. Shay Capital LLC acquired a new position in Bolt Biotherapeutics during the 3rd quarter worth approximately $85,000. Susquehanna International Group LLP acquired a new position in Bolt Biotherapeutics during the 3rd quarter worth approximately $89,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Bolt Biotherapeutics in the 4th quarter valued at approximately $112,000. Finally, T3 Companies LLC purchased a new stake in shares of Bolt Biotherapeutics in the 4th quarter valued at approximately $208,000. 86.70% of the stock is currently owned by hedge funds and other institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.